Angiotensin type 1 receptor antagonists CV-11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. 1996

X C Li, and R E Widdop
Department of Pharmacology, Monash University, Clayton, Victoria, Australia.

1. Spontaneously hypertensive rats and Wistar-Kyoto rats underwent a two-stage operation for the implantation of Doppler flow probes and intravascular catheters to determine the regional haemodynamic profiles of the angiotensin type 1 receptor antagonists, CV-11974 and EXP 3174. 2. Angiotensin II was given before and up to 24 h after the intravenous administration of CV-11974 (0.1 and 1.0 mg/kg) and EXP 3174 (1.0 mg/kg) to separate groups of conscious rats. 3. The dose of angiotensin II causing an equieffective pressor response (20-25 mmHg) was smaller in spontaneously hypertensive rats (6 ng) than in Wistar-Kyoto rats (25 ng) and was associated with marked renal and mesenteric vasoconstriction in both groups. CV-11974 (0.1 mg/kg) markedly attenuated the cardiovascular effects of angiotensin II in spontaneously hypertensive and Wistar-Kyoto rats over the subsequent 6 h. In spontaneously hypertensive rats only, CV-11974 by itself caused a progressive fall in mean arterial pressure over 6 h together with a transient increase in renal flow (1 h) and a sustained increase in renal conductance over 6 h. Minimal changes occurred in the mesenteric and hindquarters circulations. All haemodynamic variables had returned to predrug levels by 24 h. A 10-fold higher dose of CV-11974 essentially evoked a similar haemodynamic profile. In Wistar-Kyoto rats, CV-11974 did not alter regional haemodynamics except for causing a small decrease in mean arterial pressure after 4-6 h. 4. In a separate group of spontaneously hypertensive rats, EXP 3174 caused haemodynamic changes similar to those obtained using CV-11974, i.e. there was a progressive reduction in mean arterial pressure together with a transient increase in renal flow only (90 min), whereas renal conductance was elevated over 6 h. 5. The angiotensin type 1 receptor antagonists CV-11974 and EXP 3174 blocked the regional haemodynamic effects of angiotensin II and caused relatively selective renal vasodilatation in conscious spontaneously hypertensive rats only. This action is likely to contribute to the hypotensive action of angiotensin type 1 receptor antagonists in conscious spontaneously hypertensive rats.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.

Related Publications

X C Li, and R E Widdop
February 1995, Hypertension (Dallas, Tex. : 1979),
X C Li, and R E Widdop
October 1999, Hypertension (Dallas, Tex. : 1979),
X C Li, and R E Widdop
June 1993, Hypertension (Dallas, Tex. : 1979),
X C Li, and R E Widdop
June 1998, Journal of cardiovascular pharmacology,
X C Li, and R E Widdop
December 2007, British journal of pharmacology,
Copied contents to your clipboard!